This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Avalon GloboCare’s 8K filing here.
Avalon GloboCare Company Profile
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.
See Also
- Five stocks we like better than Avalon GloboCare
- Where to Find Earnings Call Transcripts
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- Using the MarketBeat Dividend Tax Calculator
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
- How Can Investors Benefit From After-Hours Trading
- Analysts See Buying Opportunity in NVIDIA Before Earnings
